Professor of Oncology and Medicine, Wayne State University School of Medicine
Oncology
Dr. Elisabeth I. Heath, MD
|
|
Give Review
Elisabeth Heath works in the field of Oncology. She went to medical school at Jefferson Medical College. She has 1 awards "Regional Top Doctor". Elisabeth Heath is a published doctor as well. She has 73 publications published. The latest was: A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer. Elisabeth I. Heath is registered with Medicare and accepts Medicare payments.
Publications
- A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid Tumors.
- A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate Cancer.
- A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate Cancer (CRPC)-a ...
- Sample size determination for logistic regression on a logit-normal distribution.
- Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate Cancer.
- Activity of enzalutamide in men with metastatic castration-resistant prostate Cancer is affected by prior treatment with abiraterone and/or docetaxel.
- Maspin expression in prostate tumor elicits Host anti-tumor immunity.
- Androgen receptor splice variants contribute to prostate Cancer aggressiveness through induction of EMT and expression of stem cell marker genes.
- Reply to g. Procopio et Al.
- Bone-induced c-kit expression in prostate Cancer: a driver of intraosseous tumor growth.
- Sunitinib Plus Androgen Deprivation and Radiation Therapy for Patients With Localized High-Risk Prostate Cancer: Results From a Multi-institutional Phase 1 Study.
- Patient, companion, and oncologist agreement regarding information discussed during triadic oncology clinical interactions.
- A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid Tumors.
- Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate C...
- A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate Cancer.
- Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate Cancer cells and the associated bone reaction.
- Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer.
- Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM.
- First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory Cancer.
- Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults.
- A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid Tumors.
- Inhibition of HDAC1 by Maspin Abrogates Epigenetic Silencing of Glutathione S-Transferase Pi (GSTp) in Prostate Carcinoma Cells.
- Participation and survival of geriatric patients in Phase I clinical trials: the Karmanos Cancer Institute (KCI) experience.
- Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid Tumors: phase I study results.
- Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid Tumors or lymphomas.
- A phase 1 study of BMS-275183, a novel oral Analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.
- A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
- A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate Cancer.
- Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate Cancer: evaluation of drug-specific biomarkers.
- Modeling using baseline characteristics in a small multicenter clinical trial for Barrett's esophagus.
- Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.
- A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate Cancer.
- Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advance...
- Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.
- A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in p...
- Malignant undifferentiated sex cord-stromal testis tumor with brain metastasis: case report.
- The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate Cancer.
- A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183.
- Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients...
- New targets in the management of prostate Cancer.
- Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with Esophageal adenoc...
- A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate Cancer.
- The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenoCarcinoma of the prostate.
- Postesophagectomy morbidity, mortality, and length of hospital stay after preoperative chemoradiation therapy.
- Phase II trial of docetaxel chemotherapy in patients with incurable adenoCarcinoma of the esophagus.
- ALK inhibitors in lung Cancer.
- A novel computerized approach to enhancing Lung tumor detection in whole-body PET images.
- Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate aminoflavone (NSC 686288) in human plasma.
- Lycopene in Cancer prevention and treatment.
- Association of human cytochrome P450 1A1 (CYP1A1) and sulfotransferase 1A1 (SULT1A1) polymorphisms with differential metabolism and cytotoxicity of aminoflavone.
- Endosonographic assessment of multimodality therapy predicts survival of esophageal Carcinoma patients.
- Gastroesophageal reflux and adenoCarcinoma of the esophagus.
- Clinical potential of matrix metalloprotease inhibitors in Cancer therapy.
- Mutations in beta-catenin and APC genes are uncommon in esophageal and esophagogastric junction adenoCarcinomas.
- Gastrointestinal Tract epithelial changes associated with taxanes: marker of drug toxicity versus effect.
- Therapy for esophageal Cancer.
- Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial Cancer, a California Cancer Consortium Trial.
- Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck Cancer.
- Soy isoflavones in conjunction with radiation therapy in patients with prostate Cancer.
- AdenoCarcinoma of the esophagus: risk factors and prevention.
- Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenoCarcinoma of the esophagus.
- Safety and efficacy of molecularly targeted agents in patients with metastatic kidney Cancer with renal dysfunction.
- Frequent hypermethylation of the 5' CpG island of E-cadherin in esophageal adenoCarcinoma.
- Epigenetic silencing of miR-34a in human prostate Cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.
- A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid Tumors.
- The role of laparoscopy in preoperative staging of esophageal Cancer.
- Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid Tumors.
- Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal Cancer treated with preoperativ...
- Chemoprevention for Barrett''s esophagus trial. Design and outcome measures.
- Secondary chemoprevention of Barrett''s esophagus with celecoxib: results of a randomized trial.
- Quantitative endoscopy in the chemoprevention of Barrett''s Esophagus Trial.
- Results from a prostate Cancer admixture mapping study in African-American men.
Schools
Jefferson Medical College Of Thomas Jefferson University Thomas Jefferson University
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Johns Hopkins University -
Georgetown University Hospital -
Jefferson Medical College
Hospital
-
DMC - Detroit Receiving Hospital -
DMC Harper University Hospital
Drug Facts
| NPI NUMBER | 1700823796 | |
| NPPES Provider LastName | HEATH | |
| NPPES Provider FirstName | ELISABETH | |
| NPPES Provider ZIPCode | 48201 | |
| NPPES Provider State | MI | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 734.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 94.0 | |
| Percent Opioid Claims | 12.81 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1700823796 |
| Last Name Of The Provider | HEATH |
| First Name Of The Provider | ELISABETH |
| View All |
Similar Doctors
|
Dr. Shabbir Ahmed, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Trailokya N. Pandit, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Joseph C. Won, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ulka N. Vaishampayan, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Shanthi Marur, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jasdeepa Nagi, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Clara Hwang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patricia M. Lorusso, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Belisario A. Arango, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sayeh M. Lavasani, MD
This Doctor is OpenDoctor Recommended.
|